Lantus

New therapies show promise in treating diabetes
New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
FDA approves 2 injectable diabetes drugsTwo new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA.
Insulin makers accused of price collusionU.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest in concerns over insulin prices.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
New diabetes drug enters competitive marketIn a major new entry in the diabetes market, FDA just approved linagliptin and metformin hydrochloride extended-release tablets (Jentadueto XR, Boehringer Ingelheim and Eli Lilly and Company) to treat type 2 diabetes.
Brand and specialty drug spending spikes
Brand and specialty drug spending spikesSpending on brand name drugs spiked 16.2% in 2015 and 98.2% since 2011, according to a new report from pharmacy benefit manager (PBM) Express Scripts. Plus, a third of branded products experienced price increases greater than 20% in 2015, according to Express Scripts’ annual Drug Trend Report.
New insulin drug to enter crowded marketNovo Nordisk is expected to find out in October whether FDA will approve its long-acting insulin Tresiba for sale in the US market. However, if approved, Tresiba faces growing competition from Sanofi, which markets the leading basal insulin Lantus along with Toujeo.
New, more potent diabetes drug approved by FDAFDA has approved a new once-daily, long-acting basal insulin, Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL, Sanofi) for the treatment of adults with type 1 and type 2 diabetes mellitus. It is described as a more potent follow-up to the manufacturer’s insulin product Lantus (insulin glargine [rDNA origin] injection, 100 U/mL).
Cholesterol-lowering agent leads list of most-prescribed drugsRosuvastatin (Crestor, AstraZeneca), a cholesterol-lowering agent, is currently the most-prescribed drug among the 100 most-prescribed and best-selling drugs in the United States. In the past 12 months, new prescriptions and refills for rosuvastatin have been estimated to amount to 23.7 million.